Patten Group, Inc. Editas Medicine, Inc. Transaction History

Patten Group, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 14, 2019	SELL	$19.43 - $26.41 $10,200 - $13,865	-525 Closed	0 $0
Q4 2018 Feb 12, 2019	SELL	$18.19 - $31.79 $3,547 - $6,199	-195 Reduced 27.08%	525 $12,000
Q3 2018 Nov 14, 2018	SELL	$27.65 - $38.39 $10,368 - $14,396	-375 Reduced 34.25%	720 $23,000
Q1 2018 May 11, 2018	SELL	$29.84 - $44.08 $3,580 - $5,289	-120 Reduced 9.88%	1,095 $36,000
Q4 2017 Feb 02, 2018	BUY	$21.89 - $31.34 $13,352 - $19,117	610 Added 100.83%	1,215 $37,000
Q3 2017 Dec 13, 2017	SELL	$15.81 - $24.01 $307,472 - $466,946	-19,448 Reduced 96.98%	605 $15,000
Q3 2017 Nov 14, 2017	BUY	$15.81 - $24.01 $317,037 - $481,472	20,053	20,053 $15,000

228

54.2M

412K

355K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $95.5M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Patten Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Patten Group, Inc. with notifications on news.